Abstract
Schizophrenia is a mental disorder with a prevalence of 0.7–1% of the general population and is characterized by impaired dopamine transmission in neurons. Recent data have shown that lysosomal storage disorders (LSD), characterized by a decrease in enzyme activity and a corresponding accumulation of substrate in lysosomes due to mutations in lysosomal genes, can manifest a wide range of clinical symptoms including psychosis, affective disorders, early onset dementia and schizophrenia. The purpose of this study was to assess the level of lysosphingolipids in patients with schizophrenia, Parkinson’s disease (PD) and control. The study included 52 patients with schizophrenia, 170 patients with PD patients and 166 neurologically healthy individuals (control group). Concentration of lysosomal substrates (hexosylsphingosine (HexSph), globotriaosylsphingosine (LysoGb3), lysosphingomyelin (LysoSM)) were measured by high-liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) in blood. An increase in the concentration of LysoSM, LysoGb3, HexSph was detected in patients with schizophrenia compared to control (p 0.0001, p 0.0001, p 0.0001, respectively). Our results confirm a violation of the lysosphingolipid composition of the blood in patients with schizophrenia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
